Thrombocytosis associated with enoxaparin: A very rare cause in newborns

Tonbul, Alparslan; Uraş, Nurdan; Tayman, Cüneyt; Halici, Tugba; Polat, Azız; Tatlı, Mustafa Mansur

doi:10.3109/09537101003649807

Cited by 7 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The diagnosis of thrombocytosis induced by drugs is challenging in the presence of other diseases. The cases that developed thrombocytosis due to drugs such as G-CSF, betalactam antibiotics, miconazole, vinca alkaloids, iron therapy, enoxaparin, antipsychotic drugs, adrenaline, glucocorticoids, retinoic acid, ciprofloxacin have been reported [7][8][9][10][11][12]. Mechanisms such as elevation of endogenous IL-6, other cytokines or catecholamines, increased megakaryocytes, increased splenic mobilization, prolonged platelet life-span have been suggested in the etiopathogenesis of ST [9].…”

Section: Discussionmentioning

confidence: 99%

Thrombocytosis Development due to the Use of Methotrexate in a Patient with Rheumatoid Arthritis

Kaydok¹,

Salbaş²

2018

Rheumatology

View full text Add to dashboard Cite

Rheumatoid arthritis is a systemic rheumatic disease that affects various organs and systems. In the course of rheumatoid arthritis, various blood disorders including thrombocytosis (>400.000/mm 3 ), an increase in the platelet count are observed. Methotrexate is a disease-modifying agent used in the treatment of Rheumatoid Arthritis and various rheumatic diseases. During methotrexate treatment, hematologic problems such as leukopenia, anemia, and thrombocytopenia are observed generally due to bone marrow suppression. In our case report, we aimed to present a 56 year-old patient who has arthritis of both hands and was diagnosed with rheumatoid arthritis and whose platelet values were initially within normal limits and then increased up to the level of 808.000/microliter despite a clinical and laboratory suppression in the disease activity after the initiation of methotrexate treatment, and quickly returned to normal values after the termination of methotrexate treatment. In conclusion, we think that the response of the blood profile to drugs may be very different, as in our case, and therefore, patients should be carefully monitored.

show abstract

Section: Discussionmentioning

confidence: 99%

Thrombocytosis Development due to the Use of Methotrexate in a Patient with Rheumatoid Arthritis

Kaydok¹,

Salbaş²

2018

Rheumatology

View full text Add to dashboard Cite

show abstract

“…None of those side effects were observed in our patients. [23][24][25] Moreover, none of the 10 patients treated with r-tPA and LMWH concomitantly had therapy-related hemorrhagic complications. Thus, combined antithrombotic and anticoagulation therapy was used safely in our study group, with a much lower incidence of hemorrhagic complications than reported in many other studies.…”

Section: Discussionmentioning

confidence: 99%

Evaluation and Treatment of Neonatal Thrombus Formation in 17 Patients

Demırel

Oğuz

Çelik

et al. 2010

Clin Appl Thromb Hemost

Self Cite

View full text Add to dashboard Cite

show abstract

“…15 To improve the application of the data to the Naranjo probability scale, adaptations were made by adding thrombocytosis-specific criteria to improve the grading of case reports for causality, as seen in Table 2. For the purpose of this review, reports of suspected thrombocytosis were systematically assessed for causality (Table 3 16-45 ). The following criteria will be utilized to assess causality of a drug by case report: number of cases described by independent investigators and the Naranjo score associated with causality.…”

Section: Methodsmentioning

confidence: 99%

“…Among the LMWHs, enoxaparin is the most widely used agent. [72][73][74][75] Four cases [28][29][30][31] and 2 case series 29,58 describing thrombocytosis after LMWH administration have been reported. On average, thrombocytosis developed 14 days (range = 3-35 days) after LMWH administration and persisted for 7 days (range = 2-48 days).…”

Section: Low-molecular-weight Heparinsmentioning

confidence: 99%

A Review and Assessment of Drug-Induced Thrombocytosis

Thompson

2018

Ann Pharmacother

View full text Add to dashboard Cite

Objectives: The purpose of this article is to review the current literature on drug-induced thrombocytosis with the goal of critically assessing causality and providing a comprehensive review of the topic. Thrombopoietic growth factors, such as thrombopoietin-receptor agonists (romiplostim and eltrombopag) and erythropoietin are not included in our review. Data Sources: The literature search included published articles limited to the English language and humans in MEDLINE, EMBASE, and Web of Science databases. MEDLINE/PubMed (1966 to September 2018) was searched using the MeSH terms thrombocytosis/chemically-induced and thrombocytosis/etiology. EMBASE (1980 to September 2018) was searched using the EMTAGS thrombocytosis/side effect. Web of Science (1970 to September 2018) was searched using the search term thrombocytosis. References of all relevant articles were reviewed for additional citations and information. Study Selection and Data Extraction: Review articles, clinical trials, background data, case series, and case reports of drug-induced thrombocytosis were collected, and case reports were assessed for causality using a modified Naranjo nomogram. Data Synthesis: Drug-induced thrombocytosis, a form of reactive thrombocytosis cannot be easily differentiated from more common etiologies of reactive thrombocytosis. In all, 43 case reports of drug-induced thrombocytosis from a wide variety of drugs and drug classes were reviewed using a modified Naranjo probability scale that included criteria specific for thrombocytosis. Conclusions: Drug-induced thrombocytosis is a relatively rare adverse drug reaction. The strongest evidence of causality supports low-molecular-weight heparins and neonatal drug withdrawal. Weaker evidence exists for all-trans retinoic acid, antibiotics, clozapine, epinephrine, gemcitabine, and vinca alkaloids.

show abstract

Thrombocytosis associated with enoxaparin: A very rare cause in newborns

Cited by 7 publications

References 10 publications

Thrombocytosis Development due to the Use of Methotrexate in a Patient with Rheumatoid Arthritis

Thrombocytosis Development due to the Use of Methotrexate in a Patient with Rheumatoid Arthritis

Evaluation and Treatment of Neonatal Thrombus Formation in 17 Patients

A Review and Assessment of Drug-Induced Thrombocytosis

Contact Info

Product

Resources

About